Source comparison
Combine BPC-157 KPV Synergy Dosing Timing — Comparison Table
Primary Mechanism VEGF upregulation, angiogenesis, eNOS activation NF-kB inhibition, cytokine suppression (IL-1, IL-6, TNF- ) Complementary. BPC-157 drives repair; KPV removes inflammatory brakes Typical Dose Range 250–500mcg per injection 500–1000mcg per inj
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, angiogenesis, eNOS activation
- NF-kB inhibition, cytokine suppression (IL-1β, IL-6, TNF-α)
- Complementary. BPC-157 drives repair; KPV removes inflammatory brakes
- Typical Dose Range
- 250–500mcg per injection
- 500–1000mcg per injection
- Use 2:1 or 1:1 KPV-to-BPC ratio based on inflammation severity
- Dosing Frequency
- Twice daily (12-hour intervals)
- Once or twice daily
- Stagger by 6–8 hours or co-administer if twice-daily KPV used
- Half-Life (Estimated)
- 4–6 hours
- 2–3 hours (effects last 6–8 hours)
- BPC-157 twice daily maintains levels; KPV once daily sufficient for sustained cytokine suppression
- Optimal Timing Relative to Injury
- Start within 24 hours (primes angiogenesis)
- Start within 12–24 hours (blocks chronic inflammation)
- Begin both concurrently during acute phase for maximum synergy
- Route of Administration
- Subcutaneous or intramuscular (oral debated)
- Subcutaneous, intramuscular, or oral (enteric-coated)
- Subcutaneous preferred for systemic repair; oral KPV requires 2–3× dose
- Storage (Lyophilized)
- Room temp 3 months; −20°C for 12–18 months
- Room temp short-term; −20°C for long-term
- Store both at −20°C if not using within 60 days
- Storage (Reconstituted)
- 2–8°C, use within 28 days
- 2–8°C, use within 21–28 days
- Refrigerate both immediately; label with reconstitution date
- Bottom Line
- Gold standard for tissue repair and angiogenesis in research
- Selective anti-inflammatory without immune suppression
- Combining them targets both proliferation and inflammation. The two rate-limiting factors in delayed healing